Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO2102 in KRAS-mutated advanced solid tumors
NCT06577532Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABO2102 in pancreatic cancer (PC) and solid tumor (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Dose-Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events up to 90 days and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
ABO2102
03
Conditions
pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT06577532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577532.